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Abstract
Nebivolol Hydrochloride (NEB) is a lipophilic molecule with low solubility in GI fluid, and high metabolism which leads to its low
oral bio availability 12%. The aim of the present investigation was to develop immediate release self emulsifying tablet (IR-SET)
as solid SMEDDS to enhance the solubility and permeability of the drug. Solubility study, pseudo-ternary phase diagrams and
32 factorial design were used to select the components of the system and optimize the composition of liquid SMEDDS. Optimal
L-SMEDDS contains Kollisolv GTA, Tween 80 and Propylene glycol as oil, surfactant and co-surfactant, respectively in the ratio
of 20:26.66:53.34 % w/w, formulates L-SMEDDS with droplet size (55.98 nm), PDI (0.37), emulsification time (16±1.52 sec)
and drug content (97.43±0.30 %). The liquid SMEDDS were adsorbed onto Neusilin US2 by adsorbtion technique to form S-
SMEDDS. DSC and SEM studies suggested that NEB in the S-SMEDDS may be present in the molecular dispersed state and
was sufficiently adsorbed onto solid carrier, respectively. S-SMEDDS was compressed into IR-SET by direct compression method
and composition of IR-SET was optimized using 32 factorial design. Optimal IR-SET showed disintegration time (92 + 0.57 sec),
droplet size (68.57 nm), PDI (0.34) and drug content (96.33±0.15 %). In vitro dissolution studies and ex vivo diffusion studies
in rat stomach suggested that SMEDDS played an important role in solubility and permeability enhancing effect. Accelerated
stability studies indicated that formulation were stable. Our results illustrated the increase in solubility and permeability of drug
from IR-SET.
Keywords: Self micro emulsifying drug delivery system (SMEDDS); Solid self micro emulsifying drug delivery system (S-
SMEDDS); immediate release self emulsifying tablet (IR-SET); Nebivolol Hydrochloride (NEB); 32 factorial design
Introduction
Poorly water soluble compounds represent an estimated 40% of
compounds in development and many major marketed drugs,
and this figure is only likely to increase and creating huge prob-
lems in pharmaceutical product development process [1]. Drug
insolubility poses significant challenges during dug development
owing to its impact on the extent and rate of drug absorption into
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the body and hence on bioavailability. It can prevent the absorp-
tion of therapeutic level of drug, delay a drug’s onset of action
and decrease its therapeutic benefit. These problems can result
in patients being given higher and more frequent drug doses,
which can result in increased therapy costs, greater likelihood
of side effects and complicated dosing regimens. The problem
of efficiently delivering these drugs has long challenged scien-
tists to develop innovative delivery systems that increase their
bioavailability. So as a part of novel drug delivery system, self
micro emulsifying drug delivery systems (SMEDDS) are also
gaining the interests. SMEDDS are isotropic mixtures of oil,
hydrophilic surfactant and/or a co-surfactant, and a solubilised
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drug. When the SMEDDS comes in the contact with the suffi-
cient water, the system forms self-emulsion and the droplet size
reduces to nano size there by increases the solubility and per-
meability of the drug molecules. This technique is very much
useful for the drug candidates which are poorly soluble and have
high log P values [2, 3]. Conventionally, SMEDDS is prepared
as liquid dosage forms that can be encapsulated in hard or soft
gelatin capsules, but liquid formulation present drug precipita-
tion and packing challenges mainly due to solvent evaporation.
Moreover, non-solid formulations are more prone to chemical
instability and capsule shell incompatibility leading to the pos-
sibility of leakage upon storage and even during handling [4].
The Solid SMEDDS are new approach to overcome above
mention problems. In this formulation the liquid self emulsify-
ing ingredients are incorporated into powder and processed to
make solid dosage form such as tablets, capsules, pellet, etc. by
using different techniques such as adsorption, spray drying, etc.
Nowadays, more focus is given on new dosage forms containing
the advantages of SMEDDS [5, 6].
Recently scientists have more focus on self emulsifying im-
mediate release tablet (IR-SETS) [7]. These tablets possess fol-
lowing advantages- they are convenient and easy to handle and
more robust, stable dosage; better compliance for patients hav-
ing allergy to capsules shells or who do not prefer to take cap-
sules. Also, these tablets have capacity to release drug faster as
compared to its capsule SMEDDS [4, 8].
Nebivolol Hydrochloride is a third generation, highly selec-
tive β adrenoceptor antagonist indicated for treatment of es-
sential hypertension. Nebivolol HCl is a lipophilic molecule.
It has low solubility in GI fluid, and high metabolism which
leads to its low absolute oral bioavailability 12%. Suitable log
P (octanol/water) of 4.03, an oral dose of a 5 mg and being
a BCS class II drug strongly provide a rationale to develop its
SMEDDS [9]. The utility of self emulsifying system in improv-
ing the dissolution of NEB has been reported [10]. However, in
the present study an attempt was made toward the use of dif-
ferent oils, surfactants and co-surfactants for the preparation of
L-SMEDDS and use of different adsorbents for preparing solid
dosage form i.e., IR-SET.
Materials and Methods
Materials
Nebivolol Hydrochloride was provided as gift sample by Em-
cure Pharmaceutical Ltd. (Pune, India). Kollisolv GTA and Kol-
lidon CL were provided as gift sample by BASF (Mumbai, In-
dia). Neusilin US2 was provided as gift sample by Gangwal
chemicals pvt. ltd., (Mumbai, India). Tween 80, Propylene gly-
col and Magnesium stearate were purchased from Loba chemie
Pvt. Ltd., Mumbai, MCC PH102 was purchased from S. D. fine
chem. Ltd., Mumbai, PVP K 30 was purchased from Sisco re-
search laboratory Pvt. Ltd., Mumbai.
Methods
Drug- Excipient compatibility studies
FTIR spectrum of NEB with the excipients i) Kollisolv GTA,
Tween 80 and Propylene glycol (L-SMEDDS) ii) SMEDDS
loaded Neusilin US2, MCC PH102, PVP K30, Kollidon CL (IR-
SET) were recorded on FTIR spectroscopy. To check for com-
patibility, the spectrums of pure NEB and NEB with excipients
were matched for appearance or disappearance of any peak [11].
Preparation of L-SMEDDS
Selection of excipients and formulation of L-SMEDDS involves
following step:
1 Solubility studies to selected excipients showing maxi-
mum drug solubility [12].
2 Emulsification efficiency of surfactants and co-surfactants
to check their ability to emulsify selected oil [11].
3 Pseudo-ternary phase diagram were constructed to obtain
the concentration range of components for the existing re-
gion of micro emulsions [13].
4 Optimization and Evaluation of NEB loaded L-SMEDDS
by 32 factorial design to observe the combined effect of the
concentration of oil as well as the concentration of Smix
(surfactant: co-surfactant) on the droplet size, emulsifica-
tion time and percent transmittance for obtaining the opti-
mized liquid SMEDDS [14–16].
Preparation of S-SMEDDS
To prepare IR-SET, the first step is to convert L-SMEDDS into
free flowing powder and to evaluate for efficient adsorption of
L-SMEDDS on adsorbent.
S-SMEDDS was prepared by mixing L-SMEDDS contain-
ing NEB with different adsorbent (Neusilin US2, Aerosil 200,
Microcrystalline cellulose PH102 and Lactose) and the angle
of repose and quantity of adsorbent required was observed as
a response. In brief L-SMEDDS was added drop wise over ad-
sorbent contained in small mortar. After each addition, mixture
was homogenized using pestle to ensure uniform distribution of
formulation. Resultant damp mass was passed through sieve no.
120 and dried at ambient temperature and stored until further
use [17].
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Scanning electron microscopy
The surface morphology of Nebivolol HCl, Neusilin US2 and S-
SMEDDS were studied by using scanning electron microscope,
the micrographs at different magnifications were recorded by
working at an excitation voltage of 10 kV [17, 18].
Differential scanning calorimetry
DSC thermograph of NEB with the excipients i) Kollisolv GTA,
Tween 80 and Propylene glycol (L-SMEDDS) ii) SMEDDS
loaded Neusilin US2, Avicel PH102, PVP K30, Kollidon CL
(IR-SET) were recorded on differential scanning calorimeter.
The thermograms of pure NEB and NEB with excipients were
matched for appearance or disappearance of any peak and en-
thalpy height [17, 18].
Optimization of IR-SET by factorial design
The objective of the present investigation was to observe the
combined effect of PVP K30 (binder) as well as Kollidon CL
(super disintegrant) on the disintegration time and friability (de-
pendent responses). Factorial design with 3 levels to estimate
curvature in response (i.e. 32factorial with total no. of experi-
ments = 9) was used [19, 20].
Preparation of self emulsifying immediate release tablets
(IR-SETS)
IR-SETS of NEB were prepared by direct compression tech-
nique. For this NEB containing S-SMEDDS and all other ex-
cipients according to the formula were weighed accurately. All
excipients were passed through sieve # 22 and mixed for 15 min-
utes. Magnesium stearate previously passed through sieve # 60
was then mixed with above blend for 5 minutes. The mixture was
then compressed into tablets using 10 station rotary tablet com-
pression machine with 10.0 mm flat round punches with tablet
weight equivalent to 450 mg [20].
Evaluation of self emulsifying immediate release tablets
(IR-SETS)
i] Friability test
The test was performed using Roche Friabilator. The device was
rotated at 25 rpm for 100 revolutions [21].
ii] Hardness
Hardness indicates the ability of tablet to withstand mechanical
shocks while handling. The hardness of tablets was determined
using Monsanto hardness tester. It is expressed in kg/cm2 [21].
iii] Disintegration test
The test was carried out using USP disintegration apparatus in
acid buffer pH 1.2 as a disintegration media maintained at 37+
2oC [21].
iv] Droplet size analysis and polydispersity index
The droplet size of the prepared formulation was determined by
photon correlation spectroscopy using NANOPHOX (NX0088).
Prepared formulation IR-SET was diluted to 100 ml with dou-
ble distilled water and the mean droplet size and polydispersity
index were determined [22].
v] Zeta potential determination
The zeta potential of the prepared formulation was determined
by Malvern Zetasizer 3000HS. Prepared IR-SET was diluted to
100 ml with double distilled water and the zeta potential was
determined [23].
vi] Drug content
The drug content of prepared formulation was determined by
placing IR-SET in 10 ml volumetric flask and diluted with
methanol. The flask was subjected to sonication for 30 minutes.
The solution was filtered through whatman filter paper and anal-
ysed using UV-Visible double beam spectrophotometer [24].
vii] In-vitro drug release
NEB loaded L-SMEDDS was filled in size ‘0’ hard gelatin cap-
sules. In-vitro release profile of L-SMEDDS and IR-SET were
studied using USP apparatus II at 37±0.5◦C with a rotating
speed of 50 rpm in dissolution media acid buffer pH 1.2, 900 ml.
During the study, 10 ml of the aliquots were removed at predeter-
mined time intervals (10, 20, 30, 40, 50, and 60 minutes) from
the dissolution medium and replaced with fresh medium. The
amount of NEB released in the dissolution medium was deter-
mined using UV-Visible double beam spectrophotometer [11].
viii] Ex-vivo release profile
For ex-vivo drug release study, stomach of previously sacrificed
Male Sprague-Dawley rat was isolated and thoroughly washed
with phosphate saline buffer pH 7.4 to remove the mucous and
lumen contents. NEB L-SMEDDS and IR-SET were diluted sep-
arately with acid buffer pH 1.2 and were filled in the stomach.
Both the ends of the tissues were tied properly to avoid any leak-
age and were placed into beaker containing 50 ml of phosphate
saline buffer pH 7.4 as the acceptor phase with the continuous
aeration supply under gentle stirring at 37±2◦C. Samples were
withdrawn from the acceptor phase at periodic time intervals and
subjected to spectrophotometric analysis [25].
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Table 1 Translation of experimentalconditions into physical unit for IR-SET
Actual Values (%) Response
Coded Values X1
PVP K30 as binder (%)
X2
Kollidon CL as super disintegrant (%)
Y1
(sec)
Y2
(%)
-1 2 2
0 3.5 3.5 Disintegration time Friability
+1 5 5
ix] Accelerated stability study
Optimized IR-SETS were packed in aluminum foil and placed
in stability chambers at 40◦C /75% RH. Formulations were
removed at each time point (0 day, 1 month and 2 months)
and evaluated for drug content and % drug release in 10 min-
utes [26].
Results & Discussion
Drug-Excipient compatibility studies
FTIR spectrum of drug, L-SMEDDS and S-SMEDDS are given
in figure 1. The principal IR absorption peaks of NEB were all
observed in the L-SMEDDS and IR-SET. These spectral obser-
vations thus indicated no interaction between the NEB and the
excipients.
Figure 1 FTIR spectrum of drug, L-SMEDDS and S-SMEDDS
Preparation of L-SMEDDS
Based on solubility studies, emulsification efficiency test
and pseudo-ternary phase diagram Kollisolv GTA, Tween 80
and Propylene glycol were selected as oil, surfactant and
co-surfactant, respectively. Composition of NEB loaded L-
SMEDDS was optimized using 32factorial design. The dif-
ferent formulations were prepared by applying factorial de-
sign using concentration of oil and Smix (surfactant and co-
surfactant) in different concentrations. Optimal L-SMEDDS
contains Kollisolv GTA, Tween 80 and Propylene glycol in
the ratio of 20:26.66:53.34 % w/w, formulates L-SMEDDS
with lower droplet size (55.98 nm), PDI (0.37), emulsification
time (16±1.52 sec), zeta potential (-26.8 mV) and drug content
(97.43±0.30 %).
Preparation of S-SMEDDS
Among the different adsorbent, Neusilin US2 has shown good
flow property (32.72±2.4) and required in 1:0.5 ratio, whereas
Aerosil 200 was also required in same ratio but shown passable
flow property (41.81±1.18) and therefore Neusilin US2 was se-
lected as adsorbent.
Table 2 Selection of adsorbent for S-SMEDDS
Adsorbent Quantity of adsorbent
required
Angle of Repose
Aerosil 200 1:0.5 41.81±1.18
(passable)
Neusilin
US2
1:0.5 32.72±2.4(good)
MCC
PH102
1:2 43.15± 1.55
(passable)
Lactose 1:1.5 37.32± 2.17 (fair)
Scanning electron microscopy
Scanning electron microscopy reveals the morphology of solid
SMEDDS. From the Figure 2 (a) Nebivolol HCl appeared to
be made of smooth rectangular crystalline structures, and from
Figure 2 (b) Neusilin US2 appeared to be spherical porous par-
ticles. Micrographs of solid SMEDDS Figure 2 (c) shows liq-
uid SMEDDS adsorbed onto the surface of Neusilin US2 parti-
cles. Crystalline structures characteristic of solid Nebivolol HCl
was not seen in solid SMEDDS micrographs suggesting that the
drug must be present in a completely dissolved state in the solid
SMEDDS.
Differential scanning calorimetry
Plain drug shows sharp endothermic peak at 233.3◦C, figure 3
(A). The sharp endothermic peak of Nebivolol HCl was replaced
with diffused peak indicating that the drug must be present in
molecularly dissolved state in L-SMEDDS, figure 3 (B). Opti-
mized IR-SET showed the disappearance of endothermic peak
of the drug which indicates the presence of drug in molecularly
dissolved state, figure 3 (C).
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Figure 2 SEM images of (a) NebivololHCl (b) Neusilin US2 (c) Solid SMEDDS
Figure 3 DSC thermogram of (A)drug, (B) L-SMEDDS, (C) IR-SET
Optimization of IR-SET by factorial design
The objective of the present investigation was to optimize the
conc. of PVP K30 and Kollidon CL mixture for preparation of
IR-SET. The results are given in Table 3.
The responses of the formulations prepared by 32 factorial
design batches are shown in Table 3. All the data were computed
by design expert software (Version 8.0.7.1). The model, which
shown a lesser P value (≤0.05) and greater F value (Table 4) was
identified as the fitting model and shown that disintegration time
and friability fitted to linear model.
The fitted regression equations relating the responses like dis-
integration time and friability are shown in the following equa-
tions, respectively. The polynomial equations can also be used to
draw conclusions considering the magnitude of co-efficient and
the mathematical sign it carries (i.e. either positive or negative).
The positive sign indicated direct effect whereas negative sign
indicated inverse effect.
Disintegration time = 128.56 − 0.67 (X1) −
30.17 (X2) ..........(1)
Friability = 0.59 − 0.15 (X1) − 9.167E −
003 (X2) ..........(2)
Graphical presentation of the data helps to show the relation-
ship between the responses and the independent variables. The
information obtained from the graphs was similar to that ob-
tained from mathematical equations by statistical analysis. (Fig-
ure 4).
Optimization (Model validation)
The solutions for numerical optimization of IR-SET were given
by design expert software. The formulation B9 was considered
for model validation. The values of responses predicted from the
obtained model by software and the results obtained by experi-
mentation are shown in Table 5. The close resemblance between
observed and predicted response values indicates the validity of
the generated model. Table 6 shows the quantity of ingredients
in optimized batch.
Evaluation of self emulsifying immediate release tablets
(IR-SETS)
i] Friability test
The optimized IR-SETS showed 0.424+0.03% friability. The fri-
ability is less than 1%, which indicates that the tablets can handle
the mechanical stress.
ii] Hardness
The optimized IR-SETS showed 2.8 + 0.29 kg/cm2hardness.
This indicates that the tablets can handle the mechanical stress.
iii] Disintegration test
The optimized IR-SETS showed 92 + 0.57 sec. This indicates
that the tablet can disintegrate and release the self emulsifying
system immediately.
iv] Droplet size analysis and polydispersity index
The optimized IR-SET showed 68.57 nm droplet size and 0.34
polydispersity index, respectively. The smaller droplet size of
the micro emulsion droplets indicates more rapid absorption and
improves the bioavailability of drug. Figure 5 shows the droplet
size distribution of optimized formula.
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Table 3 Results of B1-B9 batches
Batch X1
Conc. of PVP K30 (%)
X2
Conc. of Kollidon CL (%)
Y1
Disintegration Time (sec)
Y2
Friability (%)
B1 2.00 5.00 112±1.52 0.783±0.05
B2 2.00 2.00 156±2.08 0.756±0.03
B3 2.00 3.50 125±0.57 0.735±0.04
B4 3.50 5.00 101±1.15 0.532±0.07
B5 3.50 3.50 105±0.57 0.558±0.05
B6 3.50 2.00 169±1.15 0.515±0.05
B7 5.00 2.00 161±0.57 0.523±0.03
B8 5.00 3.50 136±1.52 0.443±0.04
B9 5.00 5.00 92±0.57 0.424±0.03
Figure 4 Responsesurface plot for (A) disintegration time and (B) friability
Table 4 ANOVA results of the measured responses (Y)
Coefficient Y1 Y2
ANOVA P Value 0.0034 0.0019
F Value 16.87 21.13
Table 5 Comparison of predicted and experimental values.
Responses Design expert B9
Predicted Experimental
Disintegration time (sec) 97.7222 92.00
Friability (%) 0.428944 0.424
Table 6 Optimized formula of IR-SET
Components % w/w
L-SMEDDS loaded Neusilin US2 Equivalent to 5 mg of NEB
PVP K30 5%
Kollidon CL 5%
Magnesium Stearate 1%
MCC PH102 q.s.
v] Zeta potential determination
Zeta potential of the optimized IR-SET was found to be -25.3
mV, indicating the stable micro emulsion.
vi] Drug content
Drug content of IR-SETS was found to be 4.81 + 0.03 mg/ml,
respectively. So, drug content in percentage was calculated and
the optimized formula had 96.33±0.15 % of drug, respectively.
Figure 5 Dropletsize distribution of optimized IR-SET
vii] In-vitro drug release
The in-vitro dissolution studies were performed in order to en-
sure the quick release of the drug in the dissolution medium.
For L-SMEDDS and IR-SET formulations, it were observed that
73.44 % and 61.28 % of the drug released within first ten min-
utes of the dissolution time, respectively. This indicates that con-
version of L-SMEDDS to IR-SET does not affect the drug re-
lease. Whereas, Plain drug and Marketed formulation, showed
only 13.79 % and 17.10 % of the drug release, respectively. This
clearly demonstrated the superior dissolution behaviour of the
developed SMEDDS as compared to Plain drug and Marketed
formulation.
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Figure 6 In-vitro drug release profile of the L-SMEDDS,
S-SMEDDS,Plain drug and Marketed formulation
viii] Ex-vivo release profile
After 2 hours of diffusion, 97.56 % of the drug was diffused
from L-SMEDDS and 93.24% of the drug was diffused from
IR-SET, while from Plain drug suspension and Marketed for-
mulation the diffusion was found to be 64.28 % and 72.73 %,
respectively. Thus, the amount of the drug diffused through the
biological membrane was more when it was given in the form
of SMEDDS formulations. The enhancement in diffusion is due
to formation of small droplets in nanometer range and improved
permeation of the NEB because of the presence of surfactant,
which reduces the interfacial tension of formulation.
Figure 7 Ex-vivo diffusion studies
ix] Accelerated stability study
The accelerated stability study was performed at 40oC/ 75% RH
for IR-SETS. The observations clearly prove that after the sta-
bility study, formulation doesn’t show significant difference, in-
dicating stability of formulations.
Conclusions
The self micro emulsifying drug delivery system was devel-
oped as a novel technique to efficiently deliver water insolu-
ble drug candidates with objective of enhanced solubility and
hence bioavailability. Nebivolol HCl was chosen as model drug
which has limited water solubility, low bioavailability, and high
partition coefficient and was best candidate for this system. L-
SMEDDS was efficiently optimised using 32 factorial design.
S-SMEDDS was efficiently prepared using Neusilin US2 by ad-
sorption technique. DSC and SEM studies suggested that NEB
in the S-SMEDDS may be present in the molecular dispersed
state and was sufficiently adsorbed onto solid carrier, respec-
tively. Composition of IR-SET was optimized using factorial
design. The different formulations were prepared by applying
by 32 factorial design using PVP K30 and Kollidon CL in dif-
ferent concentrations with disintegration time and friability as
response. The results of ANOVA indicated that all models were
significant. The close resemblance between observed and pre-
dicted response values indicated the validity of the generated
model. Optimal IR-SET contains L-SMEDDS loaded Neusilin
US2, MCC PH 102 as diluent, PVP K30 as binder, Kollidon
CL as super disintegrant and showed disintegration time (92 +
0.57 sec), friability (0.424+0.03%), hardness (2.8+0.29 kg/cm2),
droplet size (68.57 nm), PDI (0.34), zeta potential (-25.3 mV)
and drug content (96.33±0.15 %). in vitro dissolution perfor-
mance was almost similar for L-SMEDDS and IR-SET showed
73.44% and 61.28% drug release in 10 minutes, respectively
which was significantly higher than the Marketed formulation
and Plain drug. The results of ex vivo diffusion of NEB in rat
stomach suggested that SMEDDS played an important role in
absorption enhancing effect. Our results illustrated the potential
use of IR-SET to dispense poorly water soluble drug by oral
route.
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